NO852664L - Radioaktivt diagnosemiddel for paavisning av venetrombose - Google Patents
Radioaktivt diagnosemiddel for paavisning av venetromboseInfo
- Publication number
- NO852664L NO852664L NO852664A NO852664A NO852664L NO 852664 L NO852664 L NO 852664L NO 852664 A NO852664 A NO 852664A NO 852664 A NO852664 A NO 852664A NO 852664 L NO852664 L NO 852664L
- Authority
- NO
- Norway
- Prior art keywords
- neoplasminogen
- radioactive
- bound
- marked
- diagnostic agent
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title claims description 34
- 238000001514 detection method Methods 0.000 title claims description 6
- 238000003745 diagnosis Methods 0.000 title description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 28
- 229940039227 diagnostic agent Drugs 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 25
- 102000013566 Plasminogen Human genes 0.000 claims description 22
- 108010051456 Plasminogen Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 16
- 206010047249 Venous thrombosis Diseases 0.000 claims description 12
- 230000001588 bifunctional effect Effects 0.000 claims description 12
- 238000010253 intravenous injection Methods 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 11
- 239000002738 chelating agent Substances 0.000 claims description 11
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 10
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 10
- 229960005356 urokinase Drugs 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 229910021645 metal ion Inorganic materials 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 7
- 238000006149 azo coupling reaction Methods 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000009206 nuclear medicine Methods 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 4
- 230000005251 gamma ray Effects 0.000 claims description 4
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 3
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 27
- 238000005259 measurement Methods 0.000 description 23
- 208000007536 Thrombosis Diseases 0.000 description 15
- 210000002414 leg Anatomy 0.000 description 12
- 229940012957 plasmin Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108010088842 Fibrinolysin Proteins 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 102000008946 Fibrinogen Human genes 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-K pentetate(3-) Chemical compound OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QPCDCPDFJACHGM-UHFFFAOYSA-K 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108010015052 miniplasmin Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HWZUDASOMGNLSM-UHFFFAOYSA-N O=P1OCOP(=O)O1 Chemical compound O=P1OCOP(=O)O1 HWZUDASOMGNLSM-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- -1 cyclic anhydride Chemical class 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- XMBWDFGMSWQBCA-AHCXROLUSA-M iodine-123(1-) Chemical compound [123I-] XMBWDFGMSWQBCA-AHCXROLUSA-M 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940102859 methylene diphosphonate Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH322284 | 1984-07-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO852664L true NO852664L (no) | 1986-01-06 |
Family
ID=4251284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO852664A NO852664L (no) | 1984-07-04 | 1985-07-03 | Radioaktivt diagnosemiddel for paavisning av venetrombose |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0170031A1 (ja) |
| JP (1) | JPS6169733A (ja) |
| DK (1) | DK303185A (ja) |
| FI (1) | FI852492L (ja) |
| NO (1) | NO852664L (ja) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4305922A (en) * | 1978-10-04 | 1981-12-15 | University Patents, Inc. | Labeling proteins with 99m-Tc by ligand exchange |
| JPS56125317A (en) * | 1980-03-08 | 1981-10-01 | Nippon Mejifuijitsukusu Kk | Stable radioactive diagnosticum with radioactive metallic mark |
| US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
| GB2090599B (en) * | 1981-01-05 | 1984-06-13 | Novo Industri As | Stabilized plasmin compositions and method for preparation thereof |
-
1985
- 1985-06-20 EP EP85107615A patent/EP0170031A1/de not_active Withdrawn
- 1985-06-24 FI FI852492A patent/FI852492L/fi not_active Application Discontinuation
- 1985-07-03 NO NO852664A patent/NO852664L/no unknown
- 1985-07-03 DK DK303185A patent/DK303185A/da not_active Application Discontinuation
- 1985-07-03 JP JP60146444A patent/JPS6169733A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI852492L (fi) | 1986-01-05 |
| DK303185D0 (da) | 1985-07-03 |
| DK303185A (da) | 1986-01-05 |
| JPS6169733A (ja) | 1986-04-10 |
| EP0170031A1 (de) | 1986-02-05 |
| FI852492A0 (fi) | 1985-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK161015B (da) | Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop | |
| US7465434B2 (en) | Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents | |
| US4462980A (en) | Stabilized plasmin compositions and method for preparation thereof | |
| Alavi et al. | Radiolabeled antifibrin antibody in the detection of venous thrombosis: preliminary results. | |
| Morris et al. | Single photon emission computed tomography of pulmonary emboli and venous thrombi using anti–D-Dimer | |
| Johnson | Evaluation of newer techniques for the diagnosis of venous thrombosis | |
| Kempi et al. | Diagnosis of deep vein thrombosis with 99mTc-streptokinase: A clinical comparison with phlebography | |
| Krohn et al. | Radiopharmaceuticals for thrombus detection: Selection, preparation, and critical evaluation | |
| GB2090599A (en) | Stabilized plasmin compositions and method for preparation thereof | |
| NO852664L (no) | Radioaktivt diagnosemiddel for paavisning av venetrombose | |
| Knight et al. | Fragment E1 labeled with I-123 in the detection of venous thrombosis. | |
| Edenbrandt et al. | Diagnosis of deep venous thrombosis by phlebography and 99Tcm‐plasmin | |
| Coleman et al. | Radioiodinated soluble canine fibrin. Preparation and evaluation as a thrombus localizing agent in the dog. | |
| Esquerre et al. | Kinetics of technetium-labeled heparin in thromboembolism: Preliminary Report | |
| Kempi et al. | Diagnosis of deep vein thrombosis with in vivo 99m Tc-labeled red blood cells | |
| Klem et al. | Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report | |
| Edenbrandt et al. | Diagnosis of deep venous thrombosis by 99m Tc-human serum albumin microcolloid | |
| Jespersen et al. | Detection of deep vein thrombosis following myocardial infarction by the technetium-99m-plasmin test | |
| Butler et al. | Technetium-99m-modified recombinant tissue plasminogen activator to detect deep venous thrombosis | |
| Yamamoto et al. | Positive imaging of venous thrombi and thromboemboli with Ga-67 DFO-DAS-fibrinogen | |
| KR100452390B1 (ko) | 혈전을 영상화시키고 치료하기 위한 비바프시티드 기본약제 조성물 | |
| Edwards et al. | 99m Tc-NC100668, a new tracer for imaging venous thromboemboli: pre-clinical biodistribution and incorporation into plasma clots in vivo and in vitro | |
| Warlow et al. | The possible use of 125I-labeled fibrinogen for the detection of mural thrombosis following myocardial infarction | |
| DeNARDO et al. | Thrombosis detection: fibrinogen counting and radionuclide venography | |
| Weir JR et al. | VISUALISATION OF THROMBI WITH TECHNETIUM-99M UROKINASE A Negative Report |